2005
Remarkably High Frequency of EGFR Expression in Breast Carcinomas with Squamous Differentiation
Bossuyt V, Fadare O, Martel M, Ocal IT, Burtness B, Moinfar F, Leibl S, Tavassoli FA. Remarkably High Frequency of EGFR Expression in Breast Carcinomas with Squamous Differentiation. International Journal Of Surgical Pathology 2005, 13: 319-327. PMID: 16273187, DOI: 10.1177/106689690501300403.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBone NeoplasmsBreast NeoplasmsCarcinoma, AdenosquamousCarcinoma, Squamous CellCarcinosarcomaCell DifferentiationErbB ReceptorsFollow-Up StudiesHumansImmunohistochemistryKeratinsLung NeoplasmsLymph NodesLymphatic MetastasisMiddle AgedNeoplasm StagingReceptor, ErbB-2Receptors, EstrogenConceptsEpidermal growth factor receptorDisease-free survivalSquamous differentiationBreast carcinomaEstrogen receptorLymph nodesHER2 statusTissue microarrayEGFR expressionFull axillary lymph node dissectionAxillary lymph node dissectionLymph node positive breast carcinomaNode-positive breast carcinomaHuman epidermal growth factor receptorEGFR-negative tumorsLymph node dissectionPositive lymph nodesLymph node statusPositive breast carcinomaEGFR-positive tumorsEGFR-positive tumor cellsGrowth factor receptorNode dissectionEGFR positivityDistant metastasis
2004
αB‐crystallin as a marker of lymph node involvement in breast carcinoma
Chelouche‐Lev D, Kluger HM, Berger AJ, Rimm DL, Price JE. αB‐crystallin as a marker of lymph node involvement in breast carcinoma. Cancer 2004, 100: 2543-2548. PMID: 15197794, DOI: 10.1002/cncr.20304.Peer-Reviewed Original ResearchConceptsLymph node involvementBreast carcinoma cell linesBreast carcinomaNode involvementCarcinoma cell linesHuman breast carcinoma cell lineLymph node negative breast carcinomaPrimary breast carcinoma specimensLymph node positive breast carcinomaNode-positive breast carcinomaNode-negative breast carcinomaCell linesAdvanced breast carcinomaLymph node statusPredictors of survivalAlphaB-crystallinClinical prognostic markersLymph node metastasisHigh nuclear gradePrimary breast carcinomaBreast carcinoma specimensNovel tumor markerHuman breast carcinomaAlphaB-crystallin expressionIntensity of expressionPrognostic significance of phosphorylated P38 mitogen‐activated protein kinase and HER‐2 expression in lymph node‐positive breast carcinoma
Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, Bacus SS. Prognostic significance of phosphorylated P38 mitogen‐activated protein kinase and HER‐2 expression in lymph node‐positive breast carcinoma. Cancer 2004, 100: 499-506. PMID: 14745865, DOI: 10.1002/cncr.11940.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBiopsy, NeedleBreast NeoplasmsCombined Modality TherapyFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryLymph NodesMastectomyMiddle AgedMitogen-Activated Protein KinasesNeoplasm Stagingp38 Mitogen-Activated Protein KinasesProbabilityPrognosisProportional Hazards ModelsReceptor, ErbB-2Risk AssessmentSensitivity and SpecificitySurvival AnalysisTreatment OutcomeConceptsLymph node positive breast carcinomaNode-positive breast carcinomaProgression-free survivalP-p38 MAPKShorter progression-free survivalHER-2 expressionP-p38 MAPK expressionBreast carcinomaAdjuvant chemotherapyMAPK expressionKi-67Phosphorylated p38 MAPK expressionInitial cancer surgeryPrimary breast carcinomaInvasive breast carcinomaP38 MAPK expressionP38 mitogen-activated protein kinase phosphorylationPhosphorylated p38 mitogen-activated protein kinaseMitogen-activated protein kinase phosphorylationBreast carcinoma cellsAdjuvant fluorouracilMedian followCyclophosphamide chemotherapyCancer surgeryPoor outcome
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply